NLS Pharmaceutics AG (NLSP)
1.94
-0.09 (-4.43%)
At close: Jan 15, 2025, 3:59 PM
1.98
2.06%
After-hours Jan 15, 2025, 06:15 PM EST
Company Description
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders.
The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).
Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD.
The company was incorporated in 2015 and is based in Zurich, Switzerland.
NLS Pharmaceutics AG
| Country | CH |
| IPO Date | Jan 29, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Alexander Zwyer M.B.A. |
Contact Details
Address: The Circle 6 Zurich, CH | |
| Website | https://nlspharma.com |
Stock Details
| Ticker Symbol | NLSP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001783036 |
| CUSIP Number | H57830103 |
| ISIN Number | CH0523961370 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alexander Zwyer M.B.A. | Co-Founder, Chief Executive Officer & Director |
| Dr. Eric Konofal M.D., Ph.D. | Co-Founder & Chief Scientific Officer |
| Dr. George Apostol M.D. | Chief Medical Officer and Global Head of Research & Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 14, 2025 | 6-K | Filing |
| Jan 08, 2025 | 425 | Filing |
| Jan 08, 2025 | 6-K | Filing |
| Jan 07, 2025 | 6-K | Filing |
| Dec 30, 2024 | 425 | Filing |
| Dec 30, 2024 | 6-K | Filing |
| Dec 30, 2024 | F-4 | Filing |
| Dec 23, 2024 | 6-K | Filing |
| Dec 19, 2024 | 6-K/A | [Amend] Filing |
| Dec 19, 2024 | 425 | Filing |